The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin
Open accessAbstract
Objective Experiments on human erythropoietin (EPO) demonstrated that there is a direct relationship between the sialic acid-containing carbohydrate content of EPO, its circulating half-life, and in vivo bioactivity. This led to the hypothesis that an EPO analogue engineered to contain additional oligosaccharide chains would have enhanced biological activity. Darbepoetin alfa, a hyperglycosylated recombinant human EPO (rHuEPO) analogue with two extra carbohydrate chains, was designed and developed to test this hypothesis. Materials and methods Comparative pharmacokinetic and pharmacodynamic studies and biochemical analyses of darbepoetin alfa and rHuEPO were performed to define the consequences of the increased carbohydrate content. Results Due to its increased sialic acid-containing carbohydrate content, darbepoetin alfa has a higher molecular weight, a greater negative charge, and a approximately fourfold lower EPO receptor binding activity than rHuEPO. It also has a threefold longer circulating half-life than rHuEPO in rats and dogs. In spite of its lower receptor binding, and perhaps counterintuitively, darbepoetin alfa is significantly more potent in vivo than rHuEPO. Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency. Darbepoetin alfa is 3.6-fold more potent than rHuEPO in increasing the hematocrit of normal mice when each is administered thrice weekly, but when the administration frequency is reduced to once weekly, darbepoetin alfa is approximately 13-fold to 14-fold more potent than rHuEPO. Conclusions Increasing the sialic acid-containing carbohydrate content beyond the maximum found in EPO leads to a molecule with a longer circulating half-life and thereby an increased in vivo potency that can be administered less frequently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An early example worth mentioning is the development of darbepoetin alfa, an EPO molecule approved in 2001 with two additional N-oligosaccharides that increased in vivo potency and half-life [117].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
THE PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY
Greenwood, F. C., Hunter, W., & GLOVER, J. S. (1963) · Biochemical Journal · doi:10.1042/bj0890114 · Cited by 10,141
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,796
Goodman and Gilman's The Pharmacological Basis of Therapeutics
Hastings, R. C. (1996) · JAMA · doi:10.1001/jama.1996.03540120077042 · Cited by 2,375
Correction of the Anemia of End-Stage Renal Disease with Recombinant Human Erythropoietin
Eschbach, J. W., Egrie, J. C., Downing, M. R., Browne, J. K., & Adamson, J. W. (1987) · New England Journal of Medicine · doi:10.1056/nejm198701083160203 · Cited by 1,987
Self-citationWinearls, C., Pippard, M. J., Downing, M. R., Oliver, D., Reid, C. D. L., & Cotes, P. M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92192-6 · Cited by 1,401
Applied Biopharmaceutics and Pharmacokinetics.
(1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-6-826_2 · Cited by 1,209
Krantz, S. B. (1991) · Blood · doi:10.1182/blood.v77.3.419.419 · Cited by 881
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationExpression cloning of the murine erythropoietin receptor
D’Andrea, A. D., Lodish, H. F., & Wong, G. G. (1989) · Cell · doi:10.1016/0092-8674(89)90965-3 · Cited by 737
Research works printed but not linked: 1
- Sowade, 1998, The safety of treatment with recombinant human erythropoietin in clinical use, Int J Mol Med., 1, 303
Cited by
Sorted by citations
Items 401–421 of 421
Clinical Use of Hematopoietic Growth Factors
Suter, S. E. (2022) · Schalm's Veterinary Hematology · doi:10.1002/9781119500537.ch106
Chayani, S., Mokhtari, F., Kaghazian, H., Shahali, M., Emadi, R., & Ghezlou, M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4836591
Sohn, S., Sul, H., Kim, B. J., & Zang, D. Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052203
Sialylation Impacts Separation of a Biotherapeutic by Capillary Gel Electrophoresis
Osko, J. D., Zhang, Z., Semple, A., Bern, K., McIntosh, J. C., Yang, X., & Niedringhaus, T. P. (2025) · Electrophoresis · doi:10.1002/elps.70006
Hypoxic Ischemic Encephalopathy, Therapeutic Hypothermia, and Novel Combinations
Aygün, E., & Semerci, S. Y. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1011980
Development of Insulin‐Like Growth Factor Mimetic Materials
Roy, A., Dodd‐o, J., Shadpoor, B., Patel, S. K., Gharati, G., Hanna, M., Lateef‐FNU, A., Heffernan, C., & Kumar, V. (2025) · Advanced Biology · doi:10.1002/adbi.202500327
Sun, Y., Song, B., Zhang, Y., Zhang, Y., & Zhou, L. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1665405
Mise en oeuvre de dosages pour le diagnostic précoce de l'hypothyroïdie
Iss, C. (2015) · theses.fr (ABES) · doi:10.70675/f9f2aeebza5a8z4cf3zb9afzd52e7504b286
Garg, N., Muzaffar, A., Bindra, G., Mendiratta, S., & Kamal, C. M. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.118139
Khoshnood, Z., Lohrasbi, R., Hasheminejad, F., Halfinezhad, Z., Nejati, M., Norouzi, H., Jazayeri, S. H., Taleahmad, S., Gharanfoli, M., & Amiri‐Yekta, A. (2026) · 3 Biotech · doi:10.1007/s13205-026-04828-6
Park, J., Eom, D., Park, C. S., Moon, C., Kim, S., Lee, S., Lee, J., Shin, J., Jo, Y., Lee, M., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115147
Glycoform engineering of a mammalian platform to sculpt a humanized recombinant bioscavenger
Aliyu, L., Wen, J., Sunsunwal, S., Wu, J., Greenshtein, N., Wei, E., Azadi, P., Price, R., & Betenbaugh, M. J. (2026) · Cell Systems · doi:10.1016/j.cels.2026.101655
Biological Functions of Glycosylation and Their Application in Glycoengineered Therapeutics
Kubalek, C., Gardiner, S., Heaps, W. P., McCammon, K. M., Talcott, S., Argyle, M., Bundy, B. C., & Corte, D. D. (2026) · ChemEngineering · doi:10.3390/chemengineering10070085
Erythropoiesis-Targeted Doping in Sports: From Improved Oxygen Transport to Cardiovascular Risk
Chlebowska, G., Michalak, K., Mazur, Ł., & Szczurek, W. (2026) · Pathophysiology · doi:10.3390/pathophysiology33030062
Glycosylation in Quality and Safety of Therapeutic Proteins
Matsumoto, Y., Kim, J., McKenna, K. R., Biel, T. G., Kirshner, S., Falkowski, V. M., & Ju, T. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100163
Anthi, A. K., Bejan, D., Mester, S., BETHUR, N., Gonzalo-Gil, E., Benjakul, S., Aaen, K. H., Schlothauer, T., Sandlie, I., & Andersen, J. T. (2026) · Nature Communications · doi:10.1038/s41467-026-78243-z
Second-Generation Interferons: An Effective, Long-Lasting Hyperglycosylated IFN-alpha2
Ceaglio, N., Etcheverrigaray, M., Kratje, R. B., Conradt, H. S., & Oggero, M. (2011) · Springer eBooks · doi:10.1007/978-94-007-0884-6_91
An investigation of EPO as a tissue protective agent in human kidney transplantation
de Freitas, D. G. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)
Metadata
- Authors
- Egrie, J. C., Dwyer, E., Browne, J. K., Hitz, A., & Lykos, M. A.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Egrie, Joan C
- Venue
- Experimental Hematology
- Publisher
- Elsevier BV
- Published
- 2003-04
- Volume
- 31
- Issue
- 4
- Pages
- 290-299
- ISSN
- 0301-472X (ISSN-L)
- OpenAlex
- W2169177790
- Cited by
- 421
- References
- 47
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 6 · 2023: 7 · 2022: 11 · 2021: 12 · 2020: 3 · 2019: 12 · 2018: 14 · 2017: 12 · 2016: 13 · 2015: 19 · 2014: 16 · 2013: 16 · 2012: 19
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Experimental Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Keywords
- darbepoetin alfa, recombinant human erythropoietin, erythropoietin analogues, hyperglycosylation, serum half-life, in vivo potency, hematocrit, dosing frequency, pharmacokinetics, pharmacodynamics
- MeSH terms
- Darbepoetin alfa, Animals, Carbohydrates, Dogs, Dose-Response Relationship, Drug, Electrochemistry, Electrophoresis, Polyacrylamide Gel, Erythropoietin, Half-Life, Hematocrit, Humans, Kinetics, Male, Molecular Weight, Recombinant Proteins, Rats, Sprague-Dawley, Receptors, Erythropoietin, N-Acetylneuraminic Acid, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
